Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.

Filip Janku,Albiruni R. A. Razak,Ping Chi,Michael Heinrich,Margaret von Mehren,Robin L. Jones,Kristen N. Ganjoo,Jonathan C. Trent,Hans Gelderblom,Neeta Somaiah,Simin Hu,Oliver Rosen,Ying Su,Rodrigo Ruiz-Soto,Michael S. Gordon,Suzanne George

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.

2020

Filip Janku
Albiruni R. A. Razak
Ping Chi
Michael Heinrich
Margaret von Mehren
Robin L. Jones
Kristen N. Ganjoo
Jonathan C. Trent
Hans Gelderblom
Neeta Somaiah
Simin Hu
Oliver Rosen
Ying Su
Rodrigo Ruiz-Soto
Michael S. Gordon
Suzanne George

PURPOSEIn advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT/PDGFRA oncoproteins. Ripretinib is ...

Keywords:

Medicine
GiST
in patient
unmet needs
phase i study
Oncology
PDGFRA
Internal medicine
Stromal tumor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations